top of page
Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
BRD1021
Breast disease tissue array containing 102 cases of normal breasts, fibrocystic changes, proliferative breast diseases (atypical) and various types and stages of breast cancers with AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$307
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
G | |
H | |
TNM Classification: Breast carcinoma
T- Primary tumor
TX - Primary tumor cannot be assessed
TO - No evidence of primary tumor
Tis - Carcinoma in situ, intraductal carcinoma or lobular carcinoma in situ, or Paget's disease of the nipple with no tumor
T1 - Tumor 2 cm or less in greatest dimension
T2 - Tumor more than 2 cm but not more than 5 cm in greatest dimension
T3 - Tumor more than 5 cm in greasiest dimension
T4 - Tumor of any size with direct extension to chest wall or skin
N - Regional lymph nodes
NX - Regional lymph nodes cannot be assessed
NO - No regional lymph node metastasis
N1 - Metastasis to movable ipsilateral lymph node(s)
N2 - Metastasis to ipsilateral lymph nodes(s) fixed to one another or to other structure
N3 - Metastasis to ipsilateral internal mammary lymph node(s)
M - Distant metastasis
MX - Distant metastasis cannot be assessed
MO - No distant metastasis
M1 - Distant metastasis
Human
102
102
1.5mm
4um
8
13
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in various breast cancers.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | F | 43 | Breast | Normal | |||
A02 | F | 42 | Breast | Normal | |||
A03 | F | 33 | Breast | Normal | |||
A04 | F | 40 | Breast | Normal | |||
A05 | F | 39 | Breast | Normal | |||
A06 | F | 57 | Breast | Normal | |||
A07 | F | 50 | Breast | Normal | |||
A08 | F | 43 | Breast | Normal | |||
A09 | F | 27 | Breast | Normal | |||
A10 | F | 42 | Breast | Normal | |||
A11 | F | 32 | Breast | Normal | |||
A12 | F | 37 | Breast | Normal | |||
A13 | F | 45 | Breast | Normal | |||
B01 | F | 41 | Breast | Normal | |||
B02 | F | 58 | Breast | Normal | |||
B03 | F | 45 | Breast | Normal | |||
B04 | F | 33 | Breast | Normal | |||
B05 | F | 40 | Breast | Normal | |||
B06 | F | 50 | Breast | Normal | |||
B07 | F | 29 | Breast | Normal | |||
B08 | F | 42 | Breast | Normal | |||
B09 | F | 50 | Breast | Normal | |||
B10 | F | 38 | Breast | Normal | |||
B11 | F | 35 | Breast | Normal | |||
B12 | F | 54 | Breast | Normal | |||
B13 | F | 45 | Breast | Normal | |||
C01 | F | 49 | Breast | Normal | |||
C02 | F | 45 | Breast | Normal | |||
C03 | F | 33 | Breast | Normal | |||
C04 | F | 38 | Breast | Normal | |||
C05 | F | 21 | Breast | Fibroadenoma | |||
C06 | F | 23 | Breast | Fibroadenoma | |||
C07 | F | 17 | Breast | Fibroadenoma | |||
C08 | F | 25 | Breast | Fibroadenoma | |||
C09 | F | 18 | Breast | Fibroadenoma | |||
C10 | F | 25 | Breast | Fibroadenoma | |||
C11 | F | 25 | Breast | Fibroadenoma | |||
C12 | F | 12 | Breast | Fibroadenoma | |||
C13 | F | 21 | Breast | Fibroadenoma | |||
D01 | F | 34 | Breast | Fibroadenoma | |||
D02 | F | 43 | Breast | Fibrocystic changes | |||
D03 | F | 45 | Breast | Fibrocystic changes | |||
D04 | F | 42 | Breast | Fibrocystic changes | |||
D05 | F | 19 | Breast | Fibrocystic changes | |||
D06 | F | 37 | Breast | Fibrocystic changes | |||
D07 | F | 38 | Breast | Fibrocystic changes | |||
D08 | F | 51 | Breast | Fibrocystic changes | |||
D09 | F | 45 | Breast | Fibrocystic changes | |||
D10 | F | 52 | Breast | Fibrocystic changes | |||
D11 | F | 31 | Breast | Atypical hyperplasia | |||
D12 | F | 51 | Breast | Atypical hyperplasia | |||
D13 | F | 51 | Breast | Atypical hyperplasia | |||
E01 | F | 29 | Breast | Atypical hyperplasia | |||
E02 | F | 47 | Breast | Atypical hyperplasia | |||
E03 | F | 41 | Breast | Atypical hyperplasia | |||
E04 | F | 34 | Breast | Atypical hyperplasia | |||
E05 | F | 43 | Breast | Severe atypical hyperplasia | |||
E06 | F | 35 | Breast | Severe atypical hyperplasia | |||
E07 | F | 57 | Breast | Severe atypical hyperplasia | |||
E08 | F | 63 | Breast | Severe atypical hyperplasia | |||
E09 | F | 36 | Breast | Ductal carcinoma in situ | TisN0M0 | ||
E10 | F | 56 | Breast | Ductal carcinoma in situ | I | TisN1M0 | |
E11 | F | 54 | Breast | Ductal carcinoma in situ | TisN0M0 | ||
E12 | F | 48 | Breast | Ductal carcinoma in situ | TisN0M0 | ||
E13 | F | 49 | Breast | Ductal carcinoma in situ | TisN0M0 | ||
F01 | F | 21 | Breast | Ductal carcinoma in situ | TisN0M0 | ||
F02 | F | 53 | Breast | Ductal carcinoma in situ | TisN0M0 | ||
F03 | F | 80 | Breast | Invasive ductal carcinoma | I~II | T2N0M0 | |
F04 | F | 45 | Breast | Ductal carcinoma in situ | TisN0M0 | ||
F05 | F | 46 | Breast | Ductal carcinoma in situ | TisN0M0 | ||
F06 | F | 56 | Breast | Invasive lobular carcinoma | I | T2N1M0 | |
F07 | F | 47 | Breast | Invasive ductal carcinoma | I | T2N0M0 | |
F08 | F | 52 | Breast | Invasive ductal carcinoma | I | T2N1M0 | |
F09 | F | 57 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
F10 | F | 50 | Breast | Invasive lobular carcinoma | I | T2N0M0 | |
F11 | F | 75 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
F12 | F | 86 | Breast | Invasive ductal carcinoma | II | T4N0M0 | |
F13 | F | 48 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
G01 | F | 35 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
G02 | F | 44 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
G03 | F | 41 | Breast | Invasive ductal carcinoma | II | T3N0M0 | |
G04 | F | 48 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
G05 | F | 40 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
G06 | F | 33 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
G07 | F | 51 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
G08 | F | 50 | Breast | Invasive ductal carcinoma | II | T3N1M0 | |
G09 | F | 43 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
G10 | F | 38 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
G11 | F | 52 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
G12 | F | 74 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
H01 | F | 69 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
H02 | F | 40 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
H03 | F | 38 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
H04 | F | 54 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
H05 | F | 55 | Breast | Invasive ductal carcinoma | II | T4N1M0 | |
H06 | F | 60 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
H07 | F | 51 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
H08 | F | 68 | Breast | Invasive ductal carcinoma | II | T4N0M0 | |
H09 | F | 40 | Breast | Invasive ductal carcinoma | III | T2N0M0 | |
H10 | F | 36 | Breast | Invasive ductal carcinoma | III | T2N1M0 | |
H11 | F | 36 | Breast | Invasive ductal carcinoma | III | T2N0M0 | |
H12 | F | 35 | Breast | Invasive ductal carcinoma | III | T2N0M0 | |
null |
bottom of page